The Pistoia Alliance, a nonprofit alliance that advocates for greater collaboration in life sciences R&D, launched the next phase of its Chemistry, Manufacturing and Controls (CMC) Process Ontology project on Thursday. The project, which aims to develop a pharmaceutical CMC process ontology based on the ISA-88/95 framework, is supported by Eli Lilly, Amgen, Merck &… The post Pharma leaders support new Pistoia Alliance data standardization initiative appeared first on Drug Discovery and Deve...| Drug Discovery and Development
AstraZeneca announced a deal with the U.S. government to lower drug prices for American patients last Friday. According to the press release, AstraZeneca agreed “to a range of measures which will enable American patients to access medicines at prices that are equalized with those available in wealthy countries.” Under the agreement, AstraZeneca will provide Direct-to-Consumer (DTC)… The post AstraZeneca and U.S. government made a deal to lower drug prices for Americans appeared first o...| Drug Discovery and Development
Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration… The post 2025 pharma M&A surges to $70 billion in major deals appeared first on Drug Discovery and De...| Drug Discovery and Development
At a press conference in the Oval Office last week, President Donald Trump and Pfizer Chairman and CEO Albert Bourla joined hands and proudly made a joint announcement. The news...| Health Freedom Defense Fund
Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO Conference 2025.| STAT
A self-administered, under-the-skin injection version of AstraZeneca’s Saphnelo (anifrolumab-fnia) was effective for reducing disease severity in adults with systemic lupus erythematosus (SLE), according to results from an interim analysis of a Phase 3 clinical trial. “Today’s news takes us one step closer in making the clinically meaningful benefits of Saphnelo accessible for more patients with […] The post Trial testing under-the-skin Saphnelo in SLE hits main goal appeared first on...| Lupus News Today – The Web's Daily Resource for Lupus News
Middle and high school science teachers get the opportunity to learn about leading-edge cancer research and learn science skills.| cancer.ufl.edu
AstraZeneca announced May 7th it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic. A request to withdraw it from European markets had been filed since March The company also proceeded to withdraw the vaccine Vaxzevria’s marketing authorizations within Europe. It submitted a withdrawal […] The post Astrazeneca Withdraws The Covid-19 Vaccine From All Markets Because Of Declining Demand appeared first on He...| Healthcare Weekly
Das Vorgeplänkel Andexanet alfa (Ondexxya) wurde 2019 als Antidot zur Behandlung lebensbedrohlicher Blutungen unter den direkten oralen Antikoagulanzien Apixaban (Eliquis) und Rivaroxaban (Xarelto) (beides Faktor Xa-Antagonisten) zugelassen. Während es mit Idarucizumab (Praxbind) schon seit 2015 ein hochwirksames spezifisches Gegenmittel für Dabigatran (Pradaxa) gab, nach dessen Gabe man auch Notfalleingriffe und auch Thrombolysen durchführen kann, klaffte … Journal Club: ANNEXa-I: Abge...| brainpainblog
